ShareValue scores for LDX.AU: Valuation 39, Quality 37, Growth 46, Health 53.

LDX.AU
ASX

Lumos Diagnostics Holdings Ltd

A$0.13(0.00%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

-6% to 11%
Valuation
39
Overvalued
Price vs Value
Quality
37
Weak
Business Strength
Growth
46
Moderate
Revenue & Earnings
Health
53
Moderate
Financial Stability
Momentum
5
Bearish
Price Trend

Company Details

About

Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company's products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos Diagnostics Holdings Limited was incorporated in 2018 and is based in Carlsbad, California.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026